Company Overview - BiomX Inc. is a clinical-stage company focused on developing novel natural and engineered phage therapies targeting specific pathogenic bacteria [4] - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against proprietary bacterial targets [4] Upcoming Financial Results - BiomX will report its second quarter 2025 financial results and program updates before the U.S. financial markets open on August 13, 2025 [1] - A conference call and live audio webcast will be held at 8 a.m. ET on the same day to discuss these results [1][2] Conference Call Details - Registration for the conference call is recommended at least 5 minutes prior to the start [2] - The conference call can be accessed via a specific registration link, and a webcast will also be available [3]

Core Viewpoint - BiomX Inc. is set to host a conference call on May 15, 2025, to discuss its first quarter 2025 financial results and provide updates on its business and programs [1]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating specific pathogenic bacteria [3]. - The company utilizes its proprietary BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against validated bacterial targets [3].

Core Viewpoint - BiomX Inc. has disclosed a going concern qualification in its audit opinion for the fiscal year ended December 31, 2024, as required by NYSE regulations [1] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating harmful bacteria associated with chronic diseases that have significant unmet medical needs [2] - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against proprietary bacterial targets [2]